Clinical Trial Update: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Talimogene laherparepvec (Imlygic) in combination with pembrolizumab for advanced or unresectable melanoma, with results posted in 2024…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Melanoma, Recurrent Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-27